| MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies M Panda, E Kalita, S Singh, K Kumar, A Rao, VK Prajapati Life Sciences 305, 120761, 2022 | 32 | 2022 |
| High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases S Singh, K Kumar, M Panda, A Srivastava, A Mishra, VK Prajapati Molecular Diversity 27 (2), 729-751, 2023 | 17 | 2023 |
| Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics M Panda, E Kalita, S Singh, K Kumar, VK Prajapati Molecular Diversity 27 (6), 2577-2603, 2023 | 7 | 2023 |
| Mechanism of cell cycle regulation and cell proliferation during human viral infection M Panda, E Kalita, A Rao, VK Prajapati Advances in Protein Chemistry and Structural Biology 135, 497-525, 2023 | 2 | 2023 |
| Paradigms in miRNA biogenesis pathways M Panda, VK Prajapati MicroRNA in Human Infectious Diseases, 3-21, 2024 | | 2024 |
| Application of functional proteomics in understanding RNA virus-mediated infection. M Panda, E Kalita, S Singh, A Rao, VK Prajapati Advances in Protein Chemistry and Structural Biology 138, 301-325, 2023 | | 2023 |
| The interplay between circadian clock and viral infections: A molecular perspective E Kalita, M Panda, VK Prajapati Advances in Protein Chemistry and Structural Biology 137, 293-330, 2023 | | 2023 |
| Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics E Kalita, M Panda, A Rao, VK Prajapati Advances in Protein Chemistry and Structural Biology 133, 231-269, 2023 | | 2023 |
Vijay Kumar PrajapatiAssociate Professor, Department of Biochemistry, University of Delhi South CampusVerified email at south.du.ac.in
